Skip to main content
OpenTrials
Completed

NCT Number: NCT06660849

Atrial Fibrillation Duration and Cortical Lens Opacity

The prevalence of atrial fibrillation (AF) and the risk of stroke increase with a higher CHA2DS2-VASc score. Osmotic stress, which also contributes to cortical cataract formation, increases in the presence of diseases that raise the CHA2DS2-VASc score. Knowledge of AF duration is crucial because it heightens the risk of AF-related complications. This study investigated whether the presence of cortical cataracts, classified using the Lens Opacity Classification System (LOCS)stage, can predict the presence and duration of AF.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation (AF) Arrhythmias, Cardiac Atrial Fibrillation Cardiovascular Diseases Cataract Cortical Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

60 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara Atatürk Sanatoryum TR Hospital

Ankara, 06530, Turkey (Türkiye)

About this study

Atrial fibrillation (AF) is the most common type of heart rhythm disorder encountered in clinical settings and is associated with increased morbidity and mortality. The prevalence of AF and the risk of stroke increase with higher CHA2DS2-VASc scores . Cortical cataracts develop at the periphery of the lens and progress toward the center in a spoke-like pattern. The incidences of AF and cortical cataracts significantly increase with age .

Similar to subclinical AF, the initial onset of AF may go undetected, and the time required for AF to become permanent varies. Longer episodes of AF and higher CHA2DS2-VASc scores are strongly associated with an increased annual risk of stroke or systemic embolism , making it essential to estimate the duration of AF.

Cortical cataract stages can be easily identified and monitored through simple biomicroscopic examination. To our knowledge, no reliable method currently exists to predict the duration of AF of unknown onset. This study investigated the relationship between cortical cataract stages and the presence and duration of AF by analyzing p.osmolarity data and comparing it with the LAVI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Atrial Fibrillation patients

Exclusion criteria

Advanced HF (New York Heart Association class 4), Decompensated HF Prior cataract surgery Diabetic ketoacidosis Alcohol use Severe hyponatremia [sodium level of < 125 mEq/L], Nephrotic syndrome Cirrhosis Hypothyroidism

Treatment and study plan

Primary outcomes

  1. cortical cataract opacification grading.

    Time frame: day1

    All participants underwent detailed eye examinations using a biomicroscope . Digital photographs of the lenses were then captured using a smartphone under retro-illumination. Due to its simplicity, the Lens Opacity Classification System 2 [LOCS 2-Cortical] was used to perform cortical cataract opacification grading.

  2. LAVI (left atrial volume index)(ml/m2)

    Time frame: day1

    LAVI were measured using a GE Vivid N60 echocardiography system

Sponsors and collaborators

Lead sponsor

Ankara Ataturk Sanatorium Training and Research Hospital

Other Gov

Registry information

Official study title

Predicting the Presence and Duration of Atrial Fibrillation From Cortical Lens Opacity

Important dates

Study start
2017
Primary completion
2024
Study completion
2024
First posted
Oct 28, 2024
Registry last updated
Oct 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.